: Despite negativity for the FIP1L1-PDGFRA fusion gene, therapy was started with the tyrosine kinase inhibitor Imatinib.     ///    Imatinib provides a potent therapeutic option in FIP1L1-PDGFRA negative patients suffering from HES.. 